Amantadine hydrochloride may be the most common medication you've never heard of. This compound has been around for decades as the basis for antiviral and other medications, from flu therapy to treatments for brain disorders such as Parkinson's disease and the fatigue associated with multiple sclerosis.
And yet, this compound has long been a bit of an enigma because of missing information on its properties. Now, chemists at the National Institute of Standards and Technology (NIST) and collaborators have published the very first data on this important chemical's thermodynamic properties, including data on how it responds to heat and changes from a solid into a gas.
Such data are valuable to the chemical and pharmaceutical industries for getting the highest production yields and shelf life for the medication.
"Our research results are not directly related to the medical application of this multifunctional drug, although I am really fascinated by the range of its pharmacological activity," NIST research chemist Ala Bazyleva said.
"We studied its thermodynamic properties and decomposition," Bazyleva said. "It is surprising, given the long history of amantadine-based drugs, that there is almost no information like this in the literature for many of them. Chemical engineers often have to rely on estimates and predictions based on similar compounds. Collating this information and developing these types of recommendations is at the core of what our group at NIST does."
Amantadine hydrochloride belongs to a diamondoid class, a family of compounds whose structure is based on a cage of carbon atoms similar to diamond. Amantadine has a single carbon cage with a nitrogen atom attached on one side. Nonmedical studies have focused on the solid form of amantadine hydrochloride because it was expected to form disordered, or plastic, crystals, as many diamondoids do. Turns out, amantadine hydrochloride does not.
Bazyleva began studying amantadine hydrochloride years ago while in Belarus working on her doctoral dissertation, and continued the effort during her postdoctoral studies in Germany and Canada. But progress was slow, partly because adamantine hydrochloride changes from a solid directly into a gas (a process called sublimation) and simultaneously falls apart, or decomposes. She needed a model explaining this complex process, one that incorporates detailed, high-level calculations of quantum chemistry. She finally got access to this computational capability after she began working with the Thermodynamics Research Center (TRC) Group at NIST in Boulder several years ago.
"NIST was fundamental in facilitating the modeling component," Bazyleva said. "In particular, the unique combination of facilities, software and expertise in quantum chemical computations allowed us to apply high-level calculations to get insight into the structure and stability of the drug in the gas phase."
While the compound behaves like it is ionic (composed of positively and negatively charged pieces, though neutral overall) in the solid crystal form and when dissolved in a liquid, quantum chemistry calculations revealed that it decomposes into two neutral compounds in the gas phase.
The data were generated by NIST's TRC, which for more than 70 years has been producing chemical data for scientific research and industrial process design.
Co-authors are from the Belarusian State University in Belarus; the University of Rostock in Germany; and the University of Alberta in Canada.
Paper: A. Bazyleva, A.V. Blokhin, D.H. Zaitsau, G.J. Kabo, E. Paulechka, A.F. Kazakov and J.M. Shaw. Thermodynamics of the antiviral and antiparkinsonian drug amantadine hydrochloride: condensed state properties and decomposition. Journal of Chemical and Engineering Data. Published online May 1. DOI: 10.1021/acs.jced.7b00107
Story Source: Materials provided by Scienmag